1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
678FC56AD6CD55E648525768C00375173
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/marketing-new-product?opendocument
18
19opendocument
20107.23.176.162
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25SPCL




» Products & Services » »

Pharmaceutical Launch Excellence Services

ID: SMS-6


Features:

140+ Info Graphics

140+ Data Graphics

1100+ Metrics

169+ Narratives

240+ Best Practices


Pages: 439


Published: Pre-2013


Delivery Format: Shipped


Price: Price on Request

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • INCLUDED RESEARCH
Organizations are challenged to bridge the gap between what they promise and deliver. Marketing a new product in a way that excites a diverse group of customers needs diligent resource allocation strategies, integrated marketing and planning, and superior product positioning.

Now, more than ever, companies rely on successful management of
new product launches to drive superior earnings and growth. With pipeline deficits, patent expirations, price pressures and increasing development costs impacting the industry, companies that are able to achieve faster and higher sales uptake with their new products will have the advantage.

For more information on Pharmaceutical Launch Excellence Services, please contact Cameron Tew at 919-767-9246.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Consumer Products; Medical Device; Manufacturing; Chemical; Media; Service; Technology


Companies Profiled:
Abbott; Abbott Laboratories; Actelion; Alexion Pharmaceuticals; Allergan; Altus Biologics; Amgen; Amylin; ARIAD; Astellas; AstraZeneca; Bausch & Lomb; Baxter Healthcare; Baxter International; Bayer; Bayer Healthcare; Boehringer Ingelheim; Bristol-Myers Squibb; Cephalon; Dr Reddy's Laboratories; Eisai; Eli Lilly and Company; EMD Serono; Genentech; Genitope Corporation; Genzyme; GlaxoSmithKline; Human Genome Sciences; IDS Canada; Inc.; Inspire Pharmaceuticals; Integrated Communications Corp.; Intervet International (part of Schering-Plough); Janssen Cilag Pharmaceutical; Johnson & Johnson; Laboratorios Deramtologicos Darier; Lilly; Lundbeck; MedImmune; Merck; NeoVista; Neurocrine Biosciences; Nobel Biocare; Novartis; Noven Therapeuticals; Novo Nordisk; Onyx Pharmaceuticals; Pfizer; ProCaps Laboratories; ProStrakan; Quintiles; Regeneron; Roche; Sanofi-aventis; Shire; Smith & Nephew; Solvay Pharmaceuticals; Spectrum Pharmaceutical; Synapse biomedical; Takeda Pharmaceuticals; Talecris; Teva Neuroscience; Teva Pharmaceutical Industries Ltd; Ther-Rx; UCB Pharma; Vertex Pharmaceuticals; Xanodyne Pharmaceuticals


Who Can Benefit From These Services?

These services contain valuable material for each phase of the product launch cycle. Pharmaceutical executives and directors will find benchmarks useful for optimizing resources and staff, identifying trends and gaining a better understanding of the market, which will be beneficial in accomplishing their product launch objectives.




This bundle combines all of the individual research listed below into one easy-to-purchase transaction. Read individual research abstracts by clicking the titles. Return to this page to add the bundle to your cart.